Hodgkin Lymphoma - Frontline Therapy

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
09:39

ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequential Pembro & Chemo in Newly Diagnosed, Early Unfavorable, or Advanced cHL

FEATURING Jane Winter
  • 14 views
  • June 24, 2022
03:32

ASCO 2022 Conference Coverage

ASCO 2022 Correlates of Common Concerns in Older Cancer Survivors of Leukemia and Lymphoma: Results From the WHI-LILAC Study

FEATURING Melissa Loh
  • 20 views
  • June 10, 2022
45:19

Nebraska Oncology Society

CD30 CAR T-Cells in Hodgkin Lymphoma

FEATURING Natalie Grover
  • 210 views
  • June 2, 2022
17:09

Penn Medicine Abramson Cancer Center

Therapeutic Advances in Hodgkin Lymphoma

FEATURING Jakub Svoboda
  • 123 views
  • May 6, 2022
14:22

Yale Cancer Center

ASH 2021 Highlights in T-Cell Lymphoma and Hodgkin Lymphoma

FEATURING Tarsheen Sethi
  • 41 views
  • March 24, 2022
41:23

University of Colorado Division of Hematology

UC Denver ASH Review: Updates on Lymphomas

FEATURING Steven Bair
  • 84 views
  • March 16, 2022
17:03

Stephen M. Ansell

PD-1 Blockade in Hodgkin Lymphoma: Moving Up the Ranks

  • 216 views
  • March 5, 2022
14:45

SOHO 3rd Italian Conference

SOHO Italy 2021: How I Manage Hodgkin Lymphoma in the USA

FEATURING Amanda Cashen
  • 23 views
  • December 23, 2021
06:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Concurrent Pembrolizumab With AVD for Untreated Classical Hodgkin Lymphoma

FEATURING Ryan C. Lynch
  • 83 views
  • December 20, 2021
09:46

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Frontline Treatment With Pembrolizumab Followed by AVD Chemo for cHL: Updated Results and Correlative Analysis

FEATURING Pamela Allen
  • 244 views
  • December 17, 2021
16:42

Scripps Health

Strategies to Minimize Radiation Induced Heart Disease

FEATURING Prabhakar Tripuraneni
  • 165 views
  • November 15, 2021
  • 1
14:45

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021 Highlights on the Progress in Hodgkin Lymphoma: From Biology to Therapy

FEATURING Stephen M. Ansell
  • 18 views
  • October 1, 2021
16:04

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: Integrating Novel Agents Into the Treatment of Classic HL

FEATURING Ann LaCasce
  • 74 views
  • October 1, 2021
18:54

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: Treatment Strategies in Nodular Lymphocyte Predominant HL

FEATURING Ranjana Advani
  • 26 views
  • October 1, 2021
15:54

Penn Medicine Abramson Cancer Center

2021 ASCO Updates on Lymphoma and CLL

FEATURING James Gerson
  • 512 views
  • September 1, 2021
  • 1
07:18

8th Eurasian Hematology Oncology Summit

How Important Is Imaging (PET) for 1L Early Stage HL?

FEATURING Christian Gisselbrecht
  • 235 views
  • May 13, 2021
  • 2
12:15

Tatyana Feldman

Incorporating Novel Agents in 1L Therapy for Advanced cHL: PFS Data for Brentuximab Vedotin + AVD vs. ABVD, Efficacy Data for Nivo & Pembro Mono, and Nivo Combinations

  • 137 views
  • May 3, 2021
  • 1
14:10

Stephen Liu

Stage IV NSCLC ALK+ 74 y/o Male With Brain Metastases: Outcomes of Genomic Profiling - FISH Testing vs. NGS

FEATURING Julie Brahmer, Benjamin Levy
  • 708 views
  • April 1, 2021
  • 7
10:43

Otavio Baiocchi

ECHELON-1 5y Update on Brentuximab Vedotin for Stage 3/4 cHL

  • 126 views
  • April 1, 2021
20:13

UAB Hematology Review 2021

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Treatment Choices and Navigating End of Treatment PET and PET2+ Patients

FEATURING Gaurav Goyal
  • 38 views
  • March 18, 2021
07:11

Virtual West Oncology Conference

ASH Updates on Relapsed/Refractory Hodgkin Lymphomas and PTCL: What Are Our Options?

FEATURING Neha Mehta-Shah
  • 27 views
  • March 8, 2021
07:09

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

Older Adults With cHL: Considering Brentuximab Vedotin Mono & Combination Therapy as Frontline Treatments

FEATURING Jakub Svoboda
  • 132 views
  • March 5, 2021
  • 1
14:42

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Short-Course ABVD w/o RT Based on Negative Interim PET/CT?

FEATURING David Straus
  • 24 views
  • February 23, 2021
09:24

SOHO Highlights: State of the Art and Next Questions

ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Examining A+AVD vs. ABVD

FEATURING David Straus
  • 293 views
  • February 23, 2021
  • 1
11:39

SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chemotherapy Options to Improve PFS

FEATURING David Straus
  • 174 views
  • February 3, 2021

Hodgkin Lymphoma - Frontline Therapy

No subtopics